MASATAKA SUZUKI to Genetic Therapy
This is a "connection" page, showing publications MASATAKA SUZUKI has written about Genetic Therapy.
Connection Strength
1.638
-
Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Mol Ther. 2021 02 03; 29(2):505-520.
Score: 0.527
-
Recent advances in oncolytic adenovirus therapies for cancer. Curr Opin Virol. 2016 12; 21:9-15.
Score: 0.391
-
Targeted gene delivery using humanized single-chain antibody with negatively charged oligopeptide tail. Cancer Sci. 2004 May; 95(5):424-9.
Score: 0.168
-
Adenoviral gene therapy for bladder cancer. Cell. 2023 03 02; 186(5):893.
Score: 0.155
-
Three Decades of Clinical Gene Therapy: From Experimental Technologies to Viable Treatments. Mol Ther. 2021 02 03; 29(2):411-412.
Score: 0.134
-
Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Mol Ther. 2015 Sep; 23(9):1497-506.
Score: 0.091
-
Capsid-modified adenoviral vectors for improved muscle-directed gene therapy. Hum Gene Ther. 2012 Oct; 23(10):1065-70.
Score: 0.075
-
Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIII. Proc Natl Acad Sci U S A. 2011 Feb 01; 108(5):2082-7.
Score: 0.067
-
The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood. 2011 Jun 16; 117(24):6459-68.
Score: 0.017
-
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther. 2008 Sep; 16(9):1546-55.
Score: 0.014